Welcome to our dedicated page for Quantum-Si Incorporated news (Ticker: QSI), a resource for investors and traders seeking the latest updates and insights on Quantum-Si Incorporated stock.
Quantum-Si Incorporated (NASDAQ: QSI) drives innovation in proteomics through its revolutionary single-molecule detection platform. This dedicated news hub provides investors and researchers with timely updates on the company's advancements in next-generation protein sequencing technology.
Access authoritative updates including product developments, strategic partnerships, and financial disclosures. Our curated collection ensures efficient tracking of QSI's progress in creating integrated hardware-software solutions for biomolecular analysis.
Key coverage areas: platform innovations enhancing protein detection accuracy, research collaborations advancing life sciences, and operational milestones shaping the future of proteomics tools. All content is verified through primary sources to ensure reliability.
Bookmark this page for streamlined access to Quantum-Si's latest developments in transformative protein sequencing solutions. Check regularly for updates that matter to both scientific and investment communities.
Quantum-Si (Nasdaq: QSI) has announced an upcoming webinar titled 'Integrating Top-Down Mass Spectrometry and Single-Molecule Sequencing for Proteoform Analysis' scheduled for September 30, 2024. The event will feature Dr. Michael Caldwell from Northwestern University's Proteomics Center of Excellence and Dr. Meredith Carpenter from Quantum-Si.
The webinar will explore the integration of top-down mass spectrometry (TD-MS) with Quantum-Si's Platinum® instrument, showcasing how this combination offers unparalleled precision in detecting and characterizing proteins at the single-molecule level. Jeff Hawkins, CEO of Quantum-Si, emphasized the company's commitment to advancing proteomics through innovative technologies.
Dr. Caldwell highlighted the growing need for advanced technologies in proteoform characterization, stating that Quantum-Si's Platinum is a key part of their efforts in proteoform identification and discovery. The webinar aims to demonstrate how Next-Gen Protein Sequencing™ (NGPS) complements traditional approaches and enables novel discoveries in health and disease research.
Quantum-Si (Nasdaq: QSI), The Protein Sequencing Company™, has announced an Investor & Analyst event scheduled for November 20th, 2024 in New York City. The event will take place from 10 AM to 12 PM EST at the Westin NY Times Square.
During the event, Quantum-Si's management team will provide:
- Updates on market opportunities
- Insights into the technology roadmap, including new instrument offerings
- Data on novel uses of the company's detection technology beyond Next-Generation Protein Sequencing™
The event will be live streamed and include a question-and-answer session. Investors can attend in person or virtually by registering through the provided link. The webcast will be archived for at least 30 days on Quantum-Si's Investor Relations website.
Quantum-Si (Nasdaq: QSI) announced that Liberate Bio has integrated the Platinum® Next-Generation Protein Sequencer™ (NGPS) into their platform for developing novel gene therapies. Liberate is using the sequencer's protein barcoding application to screen lipid nanoparticle delivery vehicles in vivo, enhancing the precision, speed, and efficiency of their gene therapy discovery and development efforts.
The Platinum enables advanced insights into the proteome, providing characterization of protein sequence and variation at single-amino acid resolution. Unlike alternative approaches such as mass spectrometry, it does not require expensive equipment or specialized expertise. The integration has already shown transformative potential, allowing Liberate to accelerate discovery and screening efforts with reduced costs and shortened timelines.
Quantum-Si (Nasdaq: QSI), a protein sequencing company, has announced key executive appointments to drive its evolution as a leading proteomic tool provider. Todd Bennett will join as Chief Commercial Officer on September 16, 2024, bringing over 30 years of commercial leadership experience in life science tools and diagnostics. John Vieceli, Ph.D. has been named Chief Product Officer, leveraging his expertise in product development and launch from leading life sciences companies. Lindsay Thompson has been promoted to Chief Human Resources Officer, recognizing her contributions to the company's culture and talent management.
These strategic appointments aim to accelerate the global adoption of Quantum-Si's Platinum® technology and enhance product development and delivery. The company is focusing on integrating all activities from product development to customer delivery under the new Chief Product Officer role. Grace Johnston, Ph.D., has resigned as Chief Commercial Officer and will provide transitional support until September 6, 2024.
Quantum-Si (Nasdaq: QSI) announces key executive appointments to drive its evolution as a leading proteomic tool provider. Todd Bennett joins as Chief Commercial Officer, bringing over 30 years of experience in life science tools and diagnostics. John Vieceli, Ph.D., is named Chief Product Officer, leveraging his expertise in product development and launch from top DNA sequencing companies. Lindsay Thompson is promoted to Chief Human Resources Officer, recognizing her contributions to company culture and talent management.
These strategic appointments aim to accelerate the global adoption of Quantum-Si's Platinum® technology and enhance product innovation. The company also announced the resignation of Grace Johnston, Ph.D., from her role as Chief Commercial Officer. To facilitate Mr. Bennett's employment, Quantum-Si has authorized Inducement Awards including stock options and restricted stock units, subject to vesting conditions.
Quantum-Si (Nasdaq: QSI), known as The Protein Sequencing Company™, has announced its participation in the 26th Annual H.C. Wainwright Global Investment Conference. The event is scheduled to take place in New York City from September 9-11, 2024.
CEO Jeff Hawkins will be featured in a fireside chat on Tuesday, September 10th, at 4:00 PM ET. Investors and interested parties can access a live and archived webcast of the event through the 'Investors' section of Quantum-Si's website, under the Events & Presentations tab.
This participation highlights Quantum-Si's engagement with the investment community and provides an opportunity for the company to showcase its developments in protein sequencing technology to a global audience.
Quantum-Si (Nasdaq: QSI) reported its Q2 2024 financial results, highlighting revenue of $622,000 and a gross margin of 57%. The company announced the launch of its version 3 sequencing kit and plans to release two additional kits by the end of 2024. QSI completed its first full quarter of commercial launch for the Platinum® instrument.
Key financial points include:
- Net loss of $23.1 million in Q2 2024, down from $25.6 million in Q2 2023
- Adjusted EBITDA of -$22.6 million in Q2 2024
- Cash and investments totaling $218.1 million as of June 30, 2024
The company reaffirmed its 2024 guidance, projecting revenue between $3.7-$4.2 million and adjusted operating expenses under $103 million. QSI expects its current cash position to provide runway into 2026.
Quantum-Si (Nasdaq: QSI), known as The Protein Sequencing Company™, has announced its participation in the Canaccord Genuity 44th Annual Growth Conference in Boston from August 13-15, 2024. The company's CEO, Jeff Hawkins, and CFO, Jeff Keyes, will engage in a fireside chat on Tuesday, August 13th, at 11:00 AM ET.
Investors and interested parties can access a live and archived webcast of the event through the 'Investors' section of Quantum-Si's website under Events & Presentations. This participation highlights QSI's commitment to engaging with the investment community and sharing insights about their innovative protein sequencing technology.
Quantum-Si (Nasdaq: QSI), known as The Protein Sequencing Company™, has announced its plans to report second quarter 2024 financial results on August 7, 2024. The company will host a conference call and webcast on the same day at 4:30 PM ET to discuss the financial results and provide a business update.
Interested individuals can join the live webcast through the Investors section of the Quantum-Si website under Events and Presentations. Alternatively, participants can register to receive a dial-in number and personalized PIN for the call. An archived version of the webcast will be available for replay after the event.
Quantum-Si announced a presentation by Dr. Gloria Sheynkman at the Festival of Genomics and Biodata in Boston on June 12-13, 2024. The talk will cover the use of Quantum-Si’s Next-Generation Protein Sequencing (NGPS) technology to identify disease-relevant proteoforms. Dr. Sheynkman’s research involves advanced analytical methods to uncover proteomic variations driving complex diseases. The Quantum-Si platform uses dye-labeled amino acid recognizers to detect subtle variations in proteins, providing new insights into human health. The presentation will also discuss the creation of a protein isoform database and mapping splicing events related to bone mineral density in human fetal osteoblast cells.
FAQ
What is the current stock price of Quantum-Si Incorporated (QSI)?
What is the market cap of Quantum-Si Incorporated (QSI)?
